| € million | Note | 2015 | 2014 |
|---|---|---|---|
| Profit after tax | 1,124.1 | 1,164.8 | |
| Items of other comprehensive income that will not be reclassified to profit or loss in subsequent periods: |
|||
| Remeasurement of the net defined benefit liability | |||
| Changes in remeasurement | ➞ 26 | 160.5 | – 861.5 |
| Tax effect | – 45.3 | 149.2 | |
| Changes recognized in equity | 115.2 | – 712.3 | |
| 115.2 | – 712.3 | ||
| Items of other comprehensive income that may be reclassified to profit or loss in subsequent periods: |
|||
| Available-for-sale financial assets | |||
| Fair value adjustments | 18.5 | – 1.4 | |
| Reclassification to profit or loss | – 10.9 | – 0.1 | |
| Tax effect | – 2.5 | 0.4 | |
| Changes recognized in equity | 5.1 | – 1.1 | |
| Derivative financial instruments | |||
| Fair value adjustments | 725.5 | 411.7 | |
| Reclassification to profit or loss | 71.0 | – 43.0 | |
| Reclassification to assets | – 1,380.3 | – | |
| Tax effect | 15.6 | – 20.2 | |
| Changes recognized in equity | – 568.2 | 348.5 | |
| Exchange differences on translating foreign operations | |||
| Changes taken directly to equity | 971.8 | 682.4 | |
| Reclassification to profit or loss | – | 0.1 | |
| Changes recognized in equity | 971.8 | 682.5 | |
| 408.7 | 1,029.9 | ||
| Other comprehensive income | 523.9 | 317.6 | |
| Comprehensive income | 1,648.0 | 1,482.4 | |
| of which attributable to Merck KGaA shareholders | 1,635.9 | 1,469.1 | |
| of which attributable to non-controlling interests | ➞ 25 | 12.1 | 13.3 |